Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib.
Harrington P, Doores KJ, Saunders J, de Lord M, Saha C, Lechmere T, Khan H, Lam HPJ, Reilly AO, Woodley C, Asirvatham S, Dillon R, Curto-Garcia N, Sullivan JO, Kordasti S, Raj K, Malim MH, Radia D, McLornan D, Harrison C, de Lavallade H.
Harrington P, et al. Among authors: reilly ao.
Blood Cancer J. 2022 Apr 22;12(4):73. doi: 10.1038/s41408-022-00651-3.
Blood Cancer J. 2022.
PMID: 35459222
Free PMC article.
No abstract available.